Zika virus seroprevalence declines and neutralization antibodies wane in adults following outbreaks in French Polynesia and Fiji

Henderson, Alasdair D; Aubry, Maïté; Kama, Mike; Vanhomwegen, Jessica; Teissier, Anita; Mariteragi-Helle, Teheipuaura; Paoaafaite, Tuterarii; Manuguerra, Jean-Claude; Edmunds, W. John; Whitworth, Jimmy; Watson, Conall; Lau, Colleen L; Cao-Lormeau, Van-Mai; Kucharski, Adam J.

doi:10.1101/578211

Cited by 5 publications

(4 citation statements)

References 28 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The duration of protective immunity induced by ZIKV infection remains uncertain, since immunity to ZIKV infection was not studied extensively before the 2013 outbreaks. Evidence from seroprevalence studies in French Polynesia and Fiji found that levels of ZIKV neutralizing antibodies decrease with time [15]. If the fall in antibody levels means that people become susceptible to infection again, population level ZIKV immunity might be declining already.…”

Section: Introductionmentioning

confidence: 99%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

The 2015-2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection, followed by protective immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict the future age-specific risk using data from Managua, Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The imbalance in age-specific immunity implies that people in the 15-29 age range will be at highest risk of infection during the next ZIKV outbreak, increasing the expected number of congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the maximum benefit in reducing the population-level risk of infection and the risk of adverse congenital outcomes. This urgency increases if immunity is not lifelong.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

show abstract

“…According to Matheus et al . [21] and our study (data not shown), IgG raised against ZIKV and ZEDIII were still present, with at least 50% of the maximum ODr, after 300 DPSO and up to several years after infection [27]. This minor limitation could allow us to carry out retrospective seroprevalence studies of the ZIKV outbreak, whereas detecting ZIKV-induced IgG with ZEDIII could be used to detect recent past infections in populations at risk.…”

Section: Discussionmentioning

confidence: 78%

High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel

Denis¹,

Attoumani

Gravier

et al. 2019

PLoS Negl Trop Dis

View full text Add to dashboard Cite

BackgroundZika virus (ZIKV) and Dengue virus (DENV) are often co-endemic. The high protein-sequence homology of flaviviruses renders IgG induced by and directed against them highly cross-reactive against their antigen(s), as observed on a large set of sera, leading to poorly reliable sero-diagnosis.MethodsWe selected Domain III of the ZIKV Envelope (ZEDIII) sequence, which is virus specific. This recombinant domain was expressed and purified for the specific detection of ZEDIII-induced IgG by ELISA from ZIKV-RT-PCR-positive, ZIKV-IgM-positive, flavivirus-positive but ZIKV-negative, or flavivirus-negative sera. We also assessed the reactivity of ZEDIII-specific human antibodies against EDIII of DENV serotype 4 (D4EDIII) as a specific control. Sera from ZEDIII-immunized mice were also tested.ResultsCross-reactivity of IgG from 5,600 sera against total inactivated DENV or ZIKV was high (71.0% [69.1; 72.2]), whereas the specificity and sensitivity calculated using a representative cohort (242 sera) reached 90% [84.0; 95.8] and 92% [84.5; 99.5], respectively, using a ZEDIII-based ELISA. Moreover, purified human IgG against D2EDIII or D4EDIII did not bind to ZEDIII and we observed no D4EDIII reactivity with ZIKV-induced mouse polyclonal IgGs.ConclusionsWe developed a ZEDIII-based ELISA that can discriminate between past or current DENV and ZIKV infections, allowing the detection of a serological scar from other flaviviruses. This could be used to confirm exposure of pregnant women or to follow the spread of an endemic disease.

show abstract

“…Nevertheless, the seroprevalence in our cohort did not significantly change during the 12-month study period. By contrast, Handerson et al found that the seroprevalence of ZIKV in French Polynesia and Fiji significantly declined over 18 months in adults but persisted in children [ 28 ]. Although we do not have sufficient information on the seroprevalence of Zika in Thailand prior to the 2016 outbreak, it is unclear whether the absence of changes in seroprevalence in this study were related to antibody persistence or a natural boost of immunity in this area.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of Zika Virus in Amphawa District, Thailand, after the 2016 Pandemic

Sirinam

Chatchen

Arunsodsai

et al. 2022

Viruses

View full text Add to dashboard Cite

In 2016, Zika virus (ZIKV) infection was declared a public health emergency of international concern because of the neurological consequences in babies born to infected people. Because of the mild and nonspecific symptoms, serological tests are essential in epidemiological studies. However, cross-reactive antibodies between other Flaviviridae members may complicate the interpretation of results of these tests. This study investigated the seroprevalence of ZIKV infection in Samut Songkhram in central Thailand which was affected by the Zika outbreak of 2016. Three hundred and fifty volunteers aged 5–50 years in Amphawa District, Samut Songkhram, were enrolled between April 2017 and April 2018. ZIKV nonstructural protein 1 (NS1) immunoglobulin G enzyme-linked immunosorbent assay (ELISA) was used to screen serum samples collected on the first day of enrollment and after 6 and 12 months. The seroprevalence and seroconversion of ZIKV were assessed. Cases of ZIKV seroconversion were verified as evidence of ZIKV infection by NS1 blockade-of-binding ELISA and plaque reduction neutralization test (PRNT50). ZIKV seroprevalence in Amphawa was 15.1–17.8% with no significant change over the year. The total seroconversion rate throughout the year was 7/100 person-years. The ratio of asymptomatic to symptomatic infections was 4.5:1. The cases in our study confirmed the occurrence of occult ZIKV infections in the community. These undetected infections might promote the spread of ZIKV in vulnerable groups of the community.

show abstract

Zika virus seroprevalence declines and neutralization antibodies wane in adults following outbreaks in French Polynesia and Fiji

Cited by 5 publications

References 28 publications

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel

Seroprevalence of Zika Virus in Amphawa District, Thailand, after the 2016 Pandemic

Contact Info

Product

Resources

About